0 318

Cited 8 times in

Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08)

Authors
 In Young Jo  ;  Hee Chul Park  ;  Eun Seog Kim  ;  Seung-Gu Yeo  ;  Myungsoo Kim  ;  Jinsil Seong  ;  Jun Won Kim  ;  Tae Hyun Kim  ;  Won Sup Yoon  ;  Bae Kwon Jeong  ;  Sung Hwan Kim  ;  Jong Hoon Lee 
Citation
 JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.52(6) : 616-622, 2022-05 
Journal Title
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
ISSN
 0368-2811 
Issue Date
2022-05
MeSH
Carcinoma, Hepatocellular* / radiotherapy ; Humans ; Liver Neoplasms* / radiotherapy ; Lung Neoplasms* / pathology ; Radiosurgery* / adverse effects ; Retrospective Studies ; Treatment Outcome
Keywords
hepatocellular carcinoma ; pulmonary metastasis ; radiotherapy ; response
Abstract
Objective: Hypofractionated radiotherapy has recently been applied to treat pulmonary metastases of hepatocellular carcinoma. However, there is no definite evidence on its safety and efficacy. We evaluate the clinical outcomes of hypofractionated radiotherapy for oligo pulmonary metastases of hepatocellular carcinoma in the multicenter and retrospective study.

Methods: From March 2011 to February 2018, 58 patients with fewer than five pulmonary metastases of hepatocellular carcinoma who underwent hypofractionated radiotherapy in nine tertiary university hospitals were analyzed retrospectively. The primary endpoint was the local control rate. The secondary endpoints were overall survival, progression-free survival, prognostic factors affecting the treatment outcomes and treatment-related side effects.

Results: The local tumor response rate including complete and partial response was 77.6% at 3 months after hypofractionated radiotherapy. The median survival and progression-free survival times were 20.9 and 5.3 months, respectively. The 1-year overall survival and progression-free survival rates were 65.5 and 22.4%, respectively. The good treatment response after hypofractionated radiotherapy (P = 0.001), the absence of intrahepatic tumor (P = 0.004) and Child-Pugh class A (P = 0.010) were revealed as significant prognostic factors for overall survival in the multivariate analysis. A progression-free interval of <6 months (P = 0.009) was a negative prognostic factor for overall survival in the multivariate analysis. Of 58 patients, five (8.6%) had grade 2 or higher radiation pneumonitis after hypofractionated radiotherapy.

Conclusions: The favorable local control rate and acceptable toxicity indicate the clinical usefulness of hypofractionated radiotherapy for hepatocellular carcinoma patients who have less than five pulmonary metastases.
Full Text
https://academic.oup.com/jjco/article/52/6/616/6551107?login=true
DOI
10.1093/jjco/hyac028
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jun Won(김준원) ORCID logo https://orcid.org/0000-0003-1358-364X
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/189311
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links